EP1276497B1 — Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors
Assigned to Gentium SRL · Expires 2005-11-23 · 20y expired
What this patent protects
A description is given of a method of increasing the amount of stem cells and progenitor cells in the peripheral blood of a mammal; the method is characterised by the administration of defibrotide in combination or in temporal proximity with at least one haematopoietic factor, (p…
USPTO Abstract
A description is given of a method of increasing the amount of stem cells and progenitor cells in the peripheral blood of a mammal; the method is characterised by the administration of defibrotide in combination or in temporal proximity with at least one haematopoietic factor, (preferably G-CSF) having the capacity to mobilise haematopoietic progenitors.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.